Molecular Partners(MOLN)
Schlieren-Zurich, Switzerland
BiotechnologyFocus: Biologics
Molecular Partners is a life sciences company focused on Biologics.
OncologyInfectious DiseasesOphthalmology
Funding Stage
PUBLIC
Open Jobs
2
Pipeline & Clinical Trials
Ensovibep
COVID-19Clinical Trials (1)
NCT04870164Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)
Phase 1MP0317, a tri-specific fibroblast activation protein
Advanced Malignant Solid TumorClinical Trials (1)
NCT05098405First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors
Phase 1MP0274
NeoplasmsClinical Trials (1)
NCT03084926First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid Tumors
Phase 1Phase 1
Clinical Trials (1)
NCT01086761Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration
Phase 1MP0310
Advanced Solid TumorClinical Trials (1)
NCT04049903Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors
Phase 1MP0250 DARPin® drug candidate, Osimertinib
EGFR-mutated NSCLC (Disorder)Clinical Trials (1)
NCT03418532MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC
Phase 1MP0112
Diabetic Macular EdemaClinical Trials (1)
NCT01042678Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular Edema
Phase 1MP0533
LeukemiaClinical Trials (1)
NCT05673057Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1/2[212Pb]Pb-MP0712
Large Cell Neuroendocrine CarcinomaClinical Trials (1)
NCT07278479Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors
Phase 1/2MP0250
NeoplasmsClinical Trials (1)
NCT02194426First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients
Phase 1/2MP0250 plus BOR+DEX
Multiple Myeloma in RelapseClinical Trials (1)
NCT03136653A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma
Phase 1/2MP0317 + Gemcitabine + Cisplatine + Durvalumab
Advanced Biliary Tract CarcinomaClinical Trials (1)
NCT07036380MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma
Phase 2ensovibep
Covid19Clinical Trials (1)
NCT04834856Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients
Phase 2ensovibep
COVID-19Clinical Trials (1)
NCT04828161A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19
Phase 2/3LY3819253
Covid19Clinical Trials (1)
NCT04501978ACTIV-3: Therapeutics for Inpatients With COVID-19
Phase 3MP0420
COVID-19Clinical Trials (1)
NCT05780463MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
Phase 3Open Jobs (2)
Interview Prep Quick Facts
Founded: 2022
Portfolio: 16 clinical trials
Top TAs: Oncology, Infectious Diseases, Gastroenterology
Publications: 25 in PubMed
Open Roles: 2 active jobs
Therapeutic Area Focus
Marketed
Pipeline